Your browser is no longer supported. Please, upgrade your browser.
Settings
SNOA Sonoma Pharmaceuticals, Inc. daily Stock Chart
SNOA [NASD]
Sonoma Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.89 Insider Own4.00% Shs Outstand6.25M Perf Week-34.41%
Market Cap16.44M Forward P/E- EPS next Y-1.81 Insider Trans3.00% Shs Float5.94M Perf Month-31.51%
Income-12.50M PEG- EPS next Q-0.59 Inst Own22.10% Short Float0.35% Perf Quarter-30.24%
Sales17.00M P/S0.97 EPS this Y54.20% Inst Trans98.67% Short Ratio0.14 Perf Half Y-46.00%
Book/sh3.25 P/B0.81 EPS next Y35.10% ROA-55.60% Target Price9.50 Perf Year-60.69%
Cash/sh1.38 P/C1.91 EPS next 5Y- ROE-68.10% 52W Range2.46 - 7.20 Perf YTD-51.74%
Dividend- P/FCF- EPS past 5Y26.20% ROI-39.90% 52W High-63.47% Beta1.12
Dividend %- Quick Ratio3.80 Sales past 5Y0.10% Gross Margin46.50% 52W Low6.91% ATR0.20
Employees75 Current Ratio4.60 Sales Q/Q41.20% Oper. Margin-73.30% RSI (14)18.31 Volatility9.41% 5.07%
OptionableNo Debt/Eq0.03 EPS Q/Q-502.10% Profit Margin-70.50% Rel Volume0.44 Prev Close2.63
ShortableYes LT Debt/Eq0.01 EarningsJun 13 AMC Payout- Avg Volume150.57K Price2.63
Recom2.30 SMA20-27.83% SMA50-30.06% SMA200-41.37% Volume66,210 Change0.00%
Jun-14-18 08:11AM  Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi Benzinga -21.20%
Jun-13-18 04:05PM  Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results GlobeNewswire
Jun-05-18 07:05AM  U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonomas Dermatology Products in Brazil GlobeNewswire
May-31-18 07:05AM  Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call GlobeNewswire
May-25-18 01:21PM  Is Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) A Financially Sound Company? Simply Wall St.
May-08-18 07:00AM  Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer GlobeNewswire
Apr-17-18 07:04AM  Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products GlobeNewswire
Apr-09-18 07:10AM  Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharmas Antimicrobial Post-Therapy Gel ACCESSWIRE
Apr-05-18 08:06AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +14.60%
07:17AM  Sonoma Pharmaceuticals shares jump 30% premarket after FDA approves skin gel MarketWatch
07:05AM  Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel GlobeNewswire
Mar-27-18 07:05AM  Sonoma Pharmaceuticals Introduces New and Improved Acuicyn Antimicrobial Eyelid and Eyelash Hygiene Solution GlobeNewswire
Mar-09-18 07:05AM  Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018 GlobeNewswire +6.30%
Mar-07-18 10:10AM  Dawson James Securities Announces Closing of $5 Million Public Offering for Sonoma Pharmaceuticals, Inc. ACCESSWIRE
Mar-06-18 07:27PM  Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock GlobeNewswire
Mar-02-18 08:00AM  Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock GlobeNewswire +13.39%
Feb-12-18 07:10AM  Blog Exposure - Novo Nordisks Ozempic is Approved in the EU for the Treatment of Type 2 Diabetes ACCESSWIRE -8.95%
Feb-07-18 04:05PM  Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% GlobeNewswire
12:00PM  Sonoma Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jan-25-18 07:05AM  Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call GlobeNewswire
Jan-09-18 07:05AM  Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis GlobeNewswire
Jan-01-18 09:12AM  Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018 Capital Cube
Dec-05-17 07:05AM  Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn Gel Products for Management of Atopic Dermatitis GlobeNewswire
Nov-29-17 06:57PM  Does Sonoma Pharmaceuticals Incs (SNOA) Recent Track Record Look Strong? Simply Wall St.
Nov-16-17 07:45AM  Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn to Add Antimicrobial Language GlobeNewswire +7.78%
Nov-14-17 07:19PM  What You Must Know About Sonoma Pharmaceuticals Incs (SNOA) Financial Strength Simply Wall St.
Nov-09-17 04:05PM  Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million GlobeNewswire
12:40PM  Sonoma Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 07:45AM  Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products GlobeNewswire
Oct-26-17 04:05AM  Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call GlobeNewswire
Oct-25-17 10:12AM  ETFs with exposure to Sonoma Pharmaceuticals, Inc. : October 25, 2017 Capital Cube
Oct-18-17 04:30AM  Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ACCESSWIRE +5.33%
Oct-03-17 04:05AM  Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis GlobeNewswire
Sep-14-17 04:05AM  Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan GlobeNewswire
Sep-13-17 08:38PM  ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 14, 2017 Capital Cube
Aug-31-17 08:54PM  ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 1, 2017 Capital Cube
Aug-25-17 12:35PM  Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q1, 2018 By the Numbers : August 25, 2017 Capital Cube
Aug-08-17 04:05PM  Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 GlobeNewswire
10:20AM  Investor Network: Sonoma Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 04:05AM  Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call GlobeNewswire
Jul-13-17 09:57AM  CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data GlobeNewswire
04:05AM  Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data GlobeNewswire
Jul-11-17 03:01PM  ETFs with exposure to Sonoma Pharmaceuticals, Inc. : July 11, 2017 Capital Cube -5.09%
Jul-10-17 10:17AM  Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q4, 2017 By the Numbers : July 10, 2017 Capital Cube
Jun-28-17 04:05AM  Sonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Procedure Treatment and Scar Prevention GlobeNewswire
Jun-20-17 04:05AM  Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars GlobeNewswire
Jun-05-17 04:05PM  Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017 GlobeNewswire +6.02%
02:30PM  Investor Network: Sonoma Pharmaceuticals, Inc. to Host Earnings Call Accesswire
Jun-02-17 04:05AM  Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call GlobeNewswire +7.50%
Apr-12-17 04:05AM  Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® for Atopic Dermatitis and Epicyn® for Scar Management GlobeNewswire
Mar-30-17 08:15AM  Blog Coverage Sonoma Pharmaceuticals Announced FDA Clearance for Loyon Skin Descaler Accesswire
Mar-29-17 10:42AM  Sonoma Pharma Gets FDA Nod for Dry-Skin Lotion Investopedia
10:42AM  Sonoma Pharma Gets FDA Nod for Dry-Skin Lotion at Investopedia
04:05AM  Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses GlobeNewswire
Mar-23-17 04:05AM  Sonoma Pharmaceuticals Receives Final $1.5 Million Payment From Sale of Latin America Business to Invekra S.A.P.I. de C.V. GlobeNewswire
Mar-16-17 04:05AM  Sonoma Pharmaceuticals Announces Results from SebuDerm Gel Study in Treatment of Seborrheic Dermatitis GlobeNewswire +7.74%
Mar-15-17 09:30AM  Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017 Capital Cube
09:30AM  Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q3, 2017 By the Numbers : March 15, 2017
Feb-28-17 04:05AM  PetSmart® Launches the MicrocynAH® Family of Pet Healthcare Products for Dogs, Cats, Birds, Reptiles and Small Animals GlobeNewswire
Feb-23-17 01:04PM  SONOMA PHARMACEUTICALS, INC. Financials
Feb-17-17 04:45PM  SONOMA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Feb-09-17 04:32PM  SONOMA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 GlobeNewswire
Jan-31-17 04:05AM  Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer GlobeNewswire
Jan-26-17 09:00AM  With $19.5 Million in Coffers from Asset Sale, Sonoma Pharmaceuticals Sets Sights on Breakeven -- SECFilings.com Marketwired +6.64%
04:05AM  Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2017 Financial Results and Conference Call GlobeNewswire
Jan-23-17 04:10PM  SONOMA PHARMACEUTICALS, INC. Files SEC form 8-K, Amendment or Waiver to Code of Ethics, Financial Statements and Exhi
Dec-13-16 04:11PM  Weekly CFO Buys Highlights GuruFocus.com
Dec-07-16 05:11PM  SONOMA PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. Its products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis. The company's Microcyn medical devices are used for cleaning, debridement, lubricating, moistening, and dressing of acute and chronic wounds in tissue care management. It also operates a microbiology contract testing laboratory that offers consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Sonoma Pharmaceuticals, Inc. sells its products directly to end users, as well as to distributors; and through in-house sales force and call center to hospitals, physicians, nurses, and other healthcare practitioners. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Miller Robert EChief Financial OfficerMar 13Buy4.101,2004,92018,868Mar 14 09:30 PM
Miller Robert EChief Financial OfficerMar 12Buy4.031,2004,83617,668Mar 14 09:30 PM
Miller Robert EChief Financial OfficerMar 12Buy4.031,2004,83616,468Mar 13 05:42 PM
Miller Robert EChief Financial OfficerMar 09Buy3.901,2004,68015,268Mar 13 05:42 PM
Schutz James JChief Executive OfficerMar 08Buy3.992,4739,86735,858Mar 08 07:17 PM
Schutz James JChief Executive OfficerNov 30Buy4.953451,70816,174Dec 04 04:03 PM
Schutz James JChief Executive OfficerNov 29Buy5.034002,01215,829Nov 29 06:56 PM
Miller Robert EChief Financial OfficerNov 29Buy5.021,7908,99114,068Nov 30 05:09 PM
Schutz James JChief Executive OfficerNov 24Buy5.052541,28315,429Nov 27 04:03 PM
Miller Robert EChief Financial OfficerNov 21Buy5.032,00010,06512,278Nov 24 04:05 PM